Respiratory Syncytial Virus (RSV) Vaccine Research
Leveraging scientific discoveries to deliver a vaccine
Respiratory syncytial virus (RSV) is a common and pervasive cause of acute respiratory illness. Each year, it is estimated that more than 177,000 older adults are hospitalized and 14,000 of them die in the United States due to RSV.2 The disease burden of RSV in children is also staggering. Globally, there are an estimated 33 million cases of RSV annually in children less than 5 years of age, with about 3 million hospitalized and up to approximately 120,000 dying each year from complications associated with the infection.3
There are currently no immunization options approved for RSV, but Pfizer is committed to developing an RSV vaccine for both adults through direct vaccination and infants through maternal immunization.
We are recruiting participants now for a clinical trial testing an investigational RSV vaccine in adults over 60 years old. Please visit the study website to learn more.